Situación actual y evolución futura en el diagnóstico y tratamiento del angioedema hereditario
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El angioedema hereditario (EAH) es un trastorno genético raro que causa ataques de hinchazón. Los tratamientos actuales controlan los síntomas, y la terapia génica ofrece opciones personalizadas en el futuro.
Área De La Ciencia
- Genética e inmunología
- Enfermedades raras
- Farmacología
Sus Antecedentes
- El angioedema hereditario (EAH) es un trastorno genético raro caracterizado por episodios de hinchazón recurrentes.
- La forma más común (HAE-C1-INH) resulta de la deficiencia del inhibidor C1 debido a las mutaciones de SERPING1, lo que lleva a una sobreproducción de bradicinina.
- Las variantes HAE-nC1-INH implican un inhibidor C1 normal pero mutaciones en otros genes.
Objetivo Del Estudio
- Proporcionar una visión global del angioedema hereditario (EAH).
- Detallar la presentación clínica, los desafíos de diagnóstico y las estrategias terapéuticas para la HAE.
- Para resaltar los avances y las direcciones futuras en la gestión de HAE.
Principales Métodos
- Revisión de la literatura sobre la presentación clínica de la AEH.
- Análisis de las vías de diagnóstico de la HAE.
- Resumen de las opciones actuales y emergentes de tratamiento de la HAE.
Principales Resultados
- El diagnóstico de HAE puede retrasarse debido a su rareza y variedad de síntomas.
- Los tratamientos disponibles incluyen profilaxis bajo demanda, a corto plazo y a largo plazo.
- Existen cuatro opciones de profilaxis de primera línea a largo plazo, con el objetivo de controlar completamente la enfermedad.
Conclusiones
- El tratamiento eficaz de la AEH implica un diagnóstico oportuno y estrategias de tratamiento adecuadas.
- Las terapias actuales reducen significativamente la frecuencia de los ataques y mejoran la calidad de vida.
- Los tratamientos emergentes, incluida la terapia génica, son prometedores para la atención personalizada de HAE.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...